Royalty Pharma: 2025 Financial Performance And Strategic Outlook

2026-02-16 03:39:51 ET

Thesis

Royalty Pharma plc ( RPRX ) delivered decent financials in 2025. We saw double-digit growth in both Royalty Receipts and Portfolio Receipts. This led to very good returns on invested capital for the company. Elsewhere capital deployment remained pretty disciplined, with $4.7 billion in announced transactions across nine therapies, with $2.6 billion actually invested. We can also add $1.2 billion in share repurchases and a very impressive 7% dividend increase in early 2026. As for their portfolio, it is still expanding, which we want to see, with some upcoming clinical and regulatory developments, including Myqorzo, Tremfya, TEV-749, deucrictibant, and Trodelvy. There are also some strategic partnerships to look forward to, such as the Revolution Medicines collaboration for daraxonrasib, which I think will set the company up quite well for more continued top-line growth....

Read the full article on Seeking Alpha

For further details see: